Philippe Moris

4.3k citations

60 papers · 3.6k · 1 hit paper · h-index 35

Impact in

Immunology top 2%
- Immunotherapy and Immune Responses
Infectious Diseases top 2%
- Tuberculosis Research and Epidemiology

Papers in

Epidemiology 30
- Influenza Virus Research Studies 11
- Respiratory viral infections research 7
- Hepatitis B Virus Studies 7
- Cervical Cancer and HPV Research 5
Infectious Diseases 15
- Tuberculosis Research and Epidemiology 9

Co-authors: Emmanuel Hanon (4 shared papers)Opokua Ofori‐Anyinam (14 shared papers)Geert G Leroux-Roels (10 shared papers)Frédéric Clément (6 shared papers)Erik Jongert (11 shared papers)Joe Cohen (11 shared papers)Marie‐Ange Demoitié (9 shared papers)Isabel Leroux‐Roels (7 shared papers)
Journals: Vaccine (11 papers)Human Vaccines & Immunotherapeutics (7 papers)PLoS ONE (6 papers)Tuberculosis (3 papers)The Journal of Infectious Diseases (3 papers)
Partner nations: Belgium United States Switzerland

In The Last Decade

Philippe Moris

59 papers receiving 3.4k citations

Philippe Moris's Hit Papers

align trajectories log scale

Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection 2009 · 443 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2009 The Journal of Infectious Diseases

Peers

Countries citing papers authored by Philippe Moris

Since Specialization

Citations

This map shows the geographic impact of Philippe Moris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Moris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Moris more than expected).

Fields of papers citing papers by Philippe Moris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Moris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Moris. The network helps show where Philippe Moris may publish in the future.

Co-authors

The 25 scholars most cited alongside Philippe Moris, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Philippe Moris Line = papers co-authored together Philippe Moris links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 60 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection The Journal of Infectious Diseases ·Kent E. Kester, James F. Cummings, Opokua Ofori‐Anyinam, Christian F. Ockenhouse, Urszula Krzych, Philippe Moris, Robert Schwenk, Robin A. Nielsen Hit paper breakdown →	2009	443
2	Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only Vaccine ·Sandro Giannini, Emmanuel Hanon, Philippe Moris, Maxime Vanmechelen, S. Morel, Francis J. Dessy, Marc Fourneau, Brigitte Colau	2006	416
3	Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers Vaccine ·Pierre Vandepapelière, Yves Horsmans, Philippe Moris, Marcelle Van Mechelen, Michel Janssens, Marguerite Koutsoukos, Pascale Van Belle, Frédéric Clément	2008	195
4	H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses Journal of Clinical Immunology ·Philippe Moris, Robbert van der Most, Isabel Leroux‐Roels, Frédéric Clément, Mamadou Dramé, Emmanuel Hanon, Geert G Leroux-Roels, Marcelle Van Mechelen	2010	145
5	Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial Vaccine ·Isabel Leroux‐Roels, Sheron Forgus, Fien De Boever, Frédéric Clément, Marie‐Ange Demoitié, Pascal Mettens, Philippe Moris, Edouard Ledent	2012	138
6	Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting Vaccine ·Adam Penn‐Nicholson, Hennie D. Geldenhuys, Wivine Burny, Robbert van der Most, Cheryl L. Day, Erik Jongert, Philippe Moris, Mark Hatherill	2015	110
7	Induction and Regulation of T-Cell Immunity by the Novel Tuberculosis Vaccine M72/AS01 in South African Adults American Journal of Respiratory and Critical Care Medicine ·Cheryl L. Day, Michele D. Tameris, Nazma Mansoor, Michele van Rooyen, Marwou de Kock, Hennie D. Geldenhuys, Mzwandile Erasmus, Lebohang Makhethe	2013	103
8	Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial Clinical Immunology ·Geert G Leroux-Roels, Arnaud Marchant, Jack Lévy, Pierre Van Damme, Tino F. Schwarz, Yves Horsmans, Wolfgang Jilg, Peter Gottfried Kremsner	2016	100
9	Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years Human Vaccines ·Mark H. Einstein, Mira Baron, Myron J. Levin, Archana Chatterjee, Bradley Fox, Sofia Scholar, Jeffrey Bruce Rosen, Nahida A. Chakhtoura	2011	99
10	The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans Human Vaccines ·Kenneth Von Eschen, Royce A. Morrison, Madeleine Braun, Opokua Ofori‐Anyinam, Els De Kock, Priya Pavithran, Marguerite Koutsoukos, Philippe Moris	2009	96
11	Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria PLoS ONE ·Ally Olotu, Philippe Moris, Jedidah Mwacharo, Johan Vekemans, Domtila Kimani, Michel Janssens, Oscar Kai, Erik Jongert	2011	85
12	Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults PLoS ONE ·Christian F. Ockenhouse, Jason A. Regules, Donna Tosh, Jessica Cowden, April K. Kathcart, James F. Cummings, Kristopher M. Paolino, James E. Moon	2015	80
13	Protective Immunity Induced with the RTS,S/AS Vaccine Is Associated with IL-2 and TNF-α Producing Effector and Central Memory CD4+ T Cells PLoS ONE ·Joanne M. Lumsden, Robert Schwenk, Lisa Rein, Philippe Moris, Michel Janssens, Opokua Ofori‐Anyinam, Joe Cohen, Kent E. Kester	2011	79
14	Antigen-Specific IL-2 Secretion Correlates with NK Cell Responses after Immunization of Tanzanian Children with the RTS,S/AS01 Malaria Vaccine The Journal of Immunology ·Amir Horowitz, Julius Clemence R. Hafalla, Elizabeth Camp King, John Lusingu, Denise Myriam Dekker, Amanda Jane Leach, Philippe Moris, Joe Cohen	2012	78
15	A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive Adults Journal of Clinical Immunology ·Jaime C. Montoya, Juan Antonio Solon, Soledad Rosanna C. Cunanan, Luz P. Acosta, Anne Bollaerts, Philippe Moris, Michel Janssens, Erik Jongert	2013	75
16	Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-Adjuvanted Prepandemic Candidate Influenza Vaccines in Children Aged 3 to 9 Years The Pediatric Infectious Disease Journal ·Javier Díez‐Domingo, María Garcés‐Sánchez, José-Marı́a Baldó, María Victoria Planelles, Isabel Ubeda, Angels Jubert, Josep Marés, Philippe Moris	2010	69
17	Safety and immunogenicity of the M72/AS01 E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study Tuberculosis ·Paul H. Gillard, Pan‐Chyr Yang, Manfred Danilovitš, Wei‐Juin Su, Shih-Lung Cheng, Lea Pehme, Anne Bollaerts, Erik Jongert	2016	65
18	Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03 B adjuvant: Results of a randomized phase I trial Human Vaccines & Immunotherapeutics ·Jack Lévy, Laurent Licini, Edwige Haelterman, Philippe Moris, Pascal Lestrate, Silvia Damaso, Pascale Van Belle, Dominique Boutriau	2015	59
19	Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines Human Vaccines & Immunotherapeutics ·Geert G Leroux-Roels, Isabel Leroux‐Roels, Frédéric Clément, Opokua Ofori‐Anyinam, Marc Lievens, Erik Jongert, Philippe Moris, W. Ripley Ballou	2014	56
20	Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: Randomised, controlled trials Vaccine ·Isabel Leroux‐Roels, Jeanne‐Marie Devaster, Geert G Leroux-Roels, Vincent Verlant, Isabelle Henckaerts, Philippe Moris, Philippe Hermand, Pascale Van Belle	2013	56

About Philippe Moris

Philippe Moris is a scholar working on Epidemiology, Infectious Diseases, Immunology, Public Health, Environmental and Occupational Health and Virology, having authored 60 papers that have together received 3.6k indexed citations. Recurring topics across this work include Malaria Research and Control (15 papers), Influenza Virus Research Studies (11 papers), Tuberculosis Research and Epidemiology (9 papers), Immunotherapy and Immune Responses (8 papers), Respiratory viral infections research (7 papers), Mosquito-borne diseases and control (7 papers), Hepatitis B Virus Studies (7 papers) and Cervical Cancer and HPV Research (5 papers). The work is most often cited by research in Immunology (1.5k citations), Infectious Diseases (1.0k citations), Virology (225 citations), Epidemiology (1.4k citations) and Public Health, Environmental and Occupational Health (766 citations). Philippe Moris has collaborated with scholars based in Belgium, United States and Switzerland. Frequent co-authors include Emmanuel Hanon, Opokua Ofori‐Anyinam, Geert G Leroux-Roels, Frédéric Clément, Erik Jongert, Joe Cohen, Marie‐Ange Demoitié, Isabel Leroux‐Roels, Francis J. Dessy and Robbert van der Most. Their work appears in journals such as Vaccine, Human Vaccines & Immunotherapeutics, PLoS ONE, Tuberculosis and The Journal of Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Philippe Moris

Impact in

Papers in i

In The Last Decade

Philippe Moris

Philippe Moris's Hit Papers

Peers

Countries citing papers authored by Philippe Moris

Fields of papers citing papers by Philippe Moris

All Works

About Philippe Moris

Explore authors with similar magnitude of impact

Papers in